Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I.

Many men with idiopathic osteoporosis have reduced circulating insulin-like growth factor-I (IGF-I) levels. The major source of circulating IGF-I is GH-mediated production by the liver. The known anabolic effects of GH on the skeleton raised the possibility of GH deficiency in these men. We sought to test this hypothesis in this study. Fourteen men (mean age, 52.1 +/- 3.2 yr, range 31-68) with idiopathic osteoporosis were studied. Mean lumbar spine bone mineral density (BMD) was 0.723 g/cm2, T score -3.5; femoral neck BMD was 0.642 g/cm2, T score, -3.07; distal (1/3) radius BMD was 0.708 g/cm2, T score, -2.05. Eleven of 14 (79%) had frank reductions in serum IGF-I levels compared with age and sex-matched values (158.5 +/- 50 SD vs. 180 +/- 45 SD). GH secretion was stimulated by iv arginine infusion (30 g) over 30 min followed 1 h later by oral L-dopa (500 mg). Serum GH was measured at time (t) = -15, 0, 30, 45, 60, 90, 120, 150, and 180 min. All patients responded to at least one stimulus with the majority (n = 9) responding to both. Five patients responded either to arginine or to L-dopa but not to both. Baseline GH for the entire group was 0.77 + 0.08 ng/mL (SEM). Peak GH following arginine (t = 45-60 min) was 14.0 +/- 2.8 ng/mL, a 17.7 +/- 2.8-fold rise. Peak GH following L-dopa (t = 120-180 min) was 5.7 +/- 1.0 ng/mL, a 9.2 +/- 2.2-fold rise. No difference in maximal secretion was observed between those with low or normal IGF-I levels. Neither IGF-I nor IGF binding protein-3 concentrations changed significantly during the short period of GH stimulation. These data suggest that men with osteoporosis and reduced IGF-I levels do not appear to have a deficiency in the GH axis. Other hormonal or local factors may be important in regulating IGF-I expression. Deficiencies of IGF-I production at skeletal sites may be important in the pathogenesis of this syndrome.

[1]  E. Seeman,et al.  Osteoporosis in Men , 1999, Osteoporosis International.

[2]  D Dempster,et al.  Insulin-like growth factor-I in men with idiopathic osteoporosis. , 1997, The Journal of clinical endocrinology and metabolism.

[3]  H. Boer,et al.  Why retest young adults with childhood-onset growth hormone deficiency? , 1997 .

[4]  P. Hindmarsh,et al.  Peak and trough growth hormone concentrations have different associations with the insulin-like growth factor axis, body composition, and metabolic parameters. , 1997, The Journal of clinical endocrinology and metabolism.

[5]  R. Rosenfeld Is growth hormone deficiency a viable diagnosis? , 1997, The Journal of clinical endocrinology and metabolism.

[6]  Editorial: Why Retest Young Adults with Childhood-Onset Growth Hormone Deficiency? , 1997 .

[7]  E. Ghigo,et al.  The diagnosis of growth hormone deficiency in adults. , 1997, The Journal of clinical endocrinology and metabolism.

[8]  A. Rahim,et al.  The assessment of growth hormone status in normal young adult males using a variety of provocative agents , 1996, Clinical endocrinology.

[9]  P. Lips,et al.  Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men. , 1996, Bone.

[10]  A. Reutens,et al.  A highly sensitive growth hormone (GH) enzyme-linked immunosorbent assay uncovers increased contribution of a tonic mode of GH secretion in adults with organic GH deficiency. , 1996, The Journal of clinical endocrinology and metabolism.

[11]  S. Shalet,et al.  Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. , 1996, The Journal of clinical endocrinology and metabolism.

[12]  D. Schoenfeld,et al.  Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.

[13]  M. Korbonits,et al.  Diagnosis of growth hormone deficiency in adults. , 1996, Hormone research.

[14]  E. Ghigo,et al.  The diagnosis of growth hormone deficiency (GHD) in adults. , 1995 .

[15]  F. Gannon,et al.  Severe Osteoporosis in Men , 1995, Annals of Internal Medicine.

[16]  J. Zerwekh,et al.  Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  H. de Boer,et al.  Clinical aspects of growth hormone deficiency in adults. , 1995, Endocrine reviews.

[18]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[19]  G. Baumann,et al.  The Somatotrophic Axis and the Reproductive Process in Health and Disease , 1995, Serono Symposia USA Norwell, Massachusetts.

[20]  S. Inzucchi,et al.  Clinical review 61: Effects of growth hormone on human bone biology. , 1994, The Journal of clinical endocrinology and metabolism.

[21]  L. Donahue,et al.  Insulin-like Growth Factors and Bone: The Osteoporosis Connection , 1994, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[22]  A. O’Sullivan,et al.  Diagnosis of growth-hormone deficiency in adults , 1994, The Lancet.

[23]  R. Whitehouse,et al.  Reduced bone mineral density in patients with adult onset growth hormone deficiency. , 1994, The Journal of clinical endocrinology and metabolism.

[24]  H. de Boer,et al.  Diagnosis of growth hormone deficiency in adults. , 1994, Lancet.

[25]  T. Hansson,et al.  Reduced bone mineral content in adult patients with growth hormone deficiency. , 1993, Acta endocrinologica.

[26]  D. Chevenne,et al.  Variability of serum human growth hormone levels in different commercial assays: specificity of growth hormone-releasing hormone stimulation. , 1993, Hormone research.

[27]  S. Ljunghall,et al.  Low plasma levels of insulin‐like growth factor 1 (IGF‐1) in male patients with idiopathic osteoporosis , 1992, Journal of internal medicine.

[28]  A. Rowland,et al.  Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood. , 1991, The Journal of clinical endocrinology and metabolism.

[29]  P. Gluckman,et al.  Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. , 1991, The Journal of endocrinology.

[30]  M. Kleerekoper,et al.  Osteoporosis in Men: Diagnosis, Pathophysiology, and Prevention , 1990, Medicine.

[31]  R. Bowsher,et al.  Cross-reactivity of monomeric and dimeric biosynthetic human growth hormone in commercial immunoassays. , 1990, Clinical chemistry.

[32]  J. Schopohl,et al.  Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. , 1988, The Journal of clinical endocrinology and metabolism.

[33]  M. Bayer Performance criteria for appropriate characterization of "(highly) sensitive" thyrotropin assays. , 1987, Clinical chemistry.

[34]  M. Wheeler,et al.  The Role of Testosterone Measurement in the Investigation of Androgen Disorders , 1986, Annals of clinical biochemistry.

[35]  D. Clemmons,et al.  6 Factors controlling blood concentration of somatomedin C , 1984 .

[36]  D. Clemmons,et al.  Factors controlling blood concentration of somatomedin C. , 1984, Clinics in endocrinology and metabolism.

[37]  Noel Gl,et al.  Studies on prolactin in man. , 1972 .

[38]  G. L. Noel,et al.  Studies on prolactin in man. , 1972, Recent progress in hormone research.

[39]  A. Frantz,et al.  HUMAN GROWTH HORMONE. CLINICAL MEASUREMENT, RESPONSE TO HYPOGLYCEMIA AND SUPPRESSION BY CORTICOSTEROIDS. , 1964 .